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The production of prion particles in vitro by amplification
with or without exogenous seed typically results in infectivity
titers less than those associated with PrPSc isolated ex vivo and
highlights the potential role of co-factors that can catalyze dis-
ease-specific prion protein misfolding in vivo. We used a cell-
free conversion assay previously shown to replicate many
aspects of transmissible spongiform encephalopathy disease to
investigate the cellular location of disease-specific co-factors
using fractions derived from gradient centrifugation of a
scrapie-susceptible cell line. Fractions from the low density
region of the gradient doubled the efficiency of conversion of
recombinant PrP. These fractions contain plasma membrane
and cytoplasmic proteins, and conversion enhancement can be
achieved using PrPSc derived from two different strains of
mouse-passaged scrapie as seed. Equivalent fractions from a
second scrapie-susceptible cell line also stimulate conversion.
We also show that subcellular fractions enhancing disease-spe-
cific prion protein conversion prevent in vitro fibrillization of
recombinant prionprotein, suggesting the existence of separate,
competingmechanisms of disease-specific and nonspecificmis-
folding in vivo.
The transmissible spongiform encephalopathies (TSEs)5 are
a family of neurodegenerative disorders that cause disease in a
wide range of host species. TSEs include scrapie in sheep and
goats, bovine spongiform encephalopathy (BSE) in cattle,
chronic wasting disease in cervids, and different forms of dis-
ease in humans, including variant Creutzfeldt-Jakob disease.
There is also evidence for the transmission of TSEs to various
captive animal species, presumably through the consumption
of BSE-infectedmeat. TSEs have a prolonged incubation period
of many months, and clinical signs include pruritis, ataxia, and
dementia leading invariably to death. The principle pathologi-
cal manifestations include astrocytic gliosis, neuronal loss, and
spongiform degeneration. Inmost TSEs there is also deposition
of an aggregated and misfolded form of a normal cellular host
protein, PrPC, or the prion protein. During TSEs, also termed
prion diseases, the prion protein misfolds into an alternate iso-
form, PrPSc, which is composed predominately of the -sheet
and is partially protease-resistant. It is widely believed that the
disease-associated isoform, PrPSc, represents the infectious
agent of TSE diseases and is capable of using its structure as a
template for endogenous PrPC molecules after inoculation or
ingestion of PrPSc-containing preparations (1). This hypothesis
has been considerably strengthened through recent reports of
the in vitro generation of misfolded isoforms of either tissue
homogenate-derived or recombinant prion protein (recPrP)
that appear to cause TSE disease on inoculation into suitable
hosts (2–6).
A variety of different TSE strains exist that cause diseases
with distinctive pathology, clinical signs, and/or incubation
times in the samehost. It is widely believed that these strains are
encoded by different PrPSc conformations, which requires a
plethora of stable conformations to exist concomitantly (7, 8).
To account for this, it has been suggested that prion co-factors
exist that participate in misfolding of PrPC to generate PrPSc of
strain-specific conformations (8–10). Additionally, in vitro
misfolding assays that have been reported to generate de novo
infectivity almost exclusively use PrPC-enriched from or con-
tained within tissue homogenates (2, 6), whereas those assays
that use purified recPrP do not appear to generate infectivity
(11, 12) or at least not to levels allowing efficient infections of
wild type animals (3, 4, 13). These observations strongly suggest
the presence of additional factors in tissue homogenates that
facilitate prionmisfolding to genuine disease-specific isoforms.
A recent study by Deleault et al. (14) identified a minimal set
of molecules that can be added to PrPC purified from brain
homogenate to create conditions thatwill generatede novoTSE
infectivity. The PrPC co-purified with various lipidic compo-
nents and this substrate along with exogenously added
poly(A)RNA (which appears crucial) not only supported ampli-
fication of proteinase K (PK)-resistant protein when seeded
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withPrPSc but also appeared to generate PK-resistant protein in
the absence of a seed. The in vitro misfolding assay used was
based upon the proteinmisfolding cyclic amplification (PMCA)
assay, which involves serial rounds of sonication, thereby
imparting a significant amount of energy into the prion mis-
folding system. From these experiments, it cannot be ruled out
that additional, as yet undefined components also co-purified
with the PrPC from uninfected brains or that the sonication
involved in PMCA conditions creates the energy needed to
replace additional co-factors thatmay be absent from this assay
but are required in vivo.
To address these possibilities, we have begun a series of
investigations by use of a traditional cell-free conversion assay
(CFCA) in which external sources of energy (sonication or
shaking) are omitted (15, 16). We have also used bacterially
derived recombinant PrP as a substrate, and this assay, although
producing low yields of newly formed PK-resistant recombi-
nant PrP, represents a well defined system in which we know
that alterations in conversion efficiency are the result of factors
within our control. In the current studywe have used ourCFCA
to investigate whether a scrapie-susceptible, fibroblastic cell
line, LD9 (17), contains co-factors capable of enhancing PrP
misfolding.We performed subcellular fractionation of the cells
and found that low density cellular components stimulated
conversion of recombinant PrP seeded with PrPSc derived from
ME7-infectedmouse brains. These fractions were composed of
both plasma membrane and cytoplasmic proteins, and we fur-
ther showed that the same preparations enhanced prion pro-
tein conversion seeded by an alternate strain of scrapie, 79A.
Similar fractions derived from an alternate scrapie-susceptible
cell line, SMB-PS, also stimulated our ME7-seeded CFCA.
Finally, we also showed that low density fractions prevent fibril-
lization of recombinant PrP in unseeded in vitro assays, sug-
gesting that disease-specific and generic misfolding pathways
may represent differing, competing pathways of prion protein
misfolding in vivo.
EXPERIMENTAL PROCEDURES
Culture of LD9 and SMB Cells—LD9 cells were a kind gift
fromProf. CharlesWeissmann (Scripps, Florida). SMB-PS cells
were obtained from theTSEResourceCentre, Institute forAni-
mal Health, Compton, UK. All tissue cultures were maintained
in a Hera Cell 240 incubator (Heraeus) at 37 °C and 5% CO2 in
75-ml flasks. LD9 cells were maintained in Eagle’s minimal
essential media (Invitrogen) supplemented with 10% (v/v) fetal
calf serum. SMB-PS cells were maintained in Media 199 sup-
plemented with 5% (v/v) fetal calf serum and 10% (v/v) Hanks’
buffered salt solution. Cells were split when they had achieved
90% confluency, as judged by lightmicroscopy, by treating with
trypsin solution (Invitrogen) for 5 min to detach cells.
Subcellular Fractionation—Before fractionation, cells washed
with phosphate-buffered saline and the contents of a T75 flask
weremechanically lysed in 10ml of homogenization buffer (250
mM sucrose, 1 mM EDTA, 20 mM HEPES, pH 7.4, containing
EDTA-free complete protease inhibitors (Roche Applied Sci-
ence)) by 10 strokes of a Dounce homogenizer. The homoge-
nate was centrifuged briefly (10 min, 1000  g) to clear nuclei
and cellular debris to create a post-nuclear supernatant, which
was used for fractionation. 10-ml gradients of 10–20%
OptiPrep were made in Beckman Ultraclear tubes (14  89
mm) by sequentially placing 2-ml volumes of 20, 17.5, 15, 12.5,
and 10%OptiPrep solutions carefully on top of each other. The
discontinuous gradient was incubated at 4 °C for 12 h to form a
continuous gradient. A protein assay was performed on post-
nuclear supernatant by use of a 2D quant kit (Amersham Bio-
sciences), and a volume equivalent to 1.5 mg of protein (1ml)
was layered on top of each continuous OptiPrep gradient. The
tubes were centrifuged for 8 h at 228,000 g in a TH-641 rotor
(Sorvall). After centrifugation, 500-l fractions were removed
from the top of the tube to yield 22 subcellular fractions per
tube. The proteins contained in each fraction were precipitated
by the addition of 1 ml of ice-cold methanol for 12 h, and the
pellets were stored at80 °C before use.
Purification of Scrapie-associated Fibrils—The method for
isolation of scrapie-associated fibrils has previously been pub-
lished (18) and is based around detergent extraction and differ-
ential centrifugation. More details can be found in the
supplemental Materials and Methods.
Production of Murine Wild type and 3F4 Recombinant PrP—
We have previously published details of the basic expression
and purification procedures applied to bacterial-expressed,
wild type, murine recombinant PrP (19). A construct for3F4-
recPrPwas generated by introducing themutations L108Mand
V111M by site-directed mutagenesis (QuikChange, Strat-
agene). More details of the purification strategy adopted are
contained within supplemental Materials and Methods, but
recPrP was isolated from bacteria by lysis with lysozyme, inclu-
sion bodies were solubilized in a urea containing buffer, and
recPrP was purified by metal ion affinity chromatography and
cation exchange chromatography. Purified protein was oxi-
dized and then dialyzed extensively against sodium acetate.
Final protein solutions were concentrated to 1 mg/ml and
stored at80 °C before use.
Cell-free Conversion Assays—Details of our CFCA procedure
have previously been published (15), and more details can be
found in the supplemental Materials and Methods. In the cur-
rent experiments we supplemented our standard cell-free con-
version assay with fractions derived from subcellular fraction-
ation and treated the assay as normal. CFCA conversion
efficiencies were tested for deviations from control reactions by
one-sample t tests and were deemed significant if p 0.05.
SDS-PAGE and Western Blotting—The NuPAGE system
(Invitrogen) was used for all SDS-PAGE separations. Samples
for analysis were diluted 3:1 with 4 LDS sample buffer and
heated for 10 min in a boiling water bath. Proteins were
resolved on pre-cast 12% Bis-Tris NuPAGE gels (Invitrogen),
and 5 l of SeeBlue Plus was used as the molecular weight
standard. Pre-cast gels were electrophoresed at 170 V for
approximately 1 h and were either visualized by Coomassie
Brilliant Blue or silver staining or used for Western blotting.
SDS-PAGE gels were blotted to polyvinylidene difluoride
membranes (Millipore) by use of a semidry blotter (Invitrogen)
for 1 h 30min at 100mA. Themembrane was blocked for 1 h at
room temperature in 5% Marvel solution and probed with
either 3F4 anti-PrP monoclonal antibody (TSE Resource Cen-
tre) or antibodies specific to chosen subcellular marker pro-
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teins. Goat anti-mouse secondary antibody coupled to horse-
radish peroxidase was used, and the signal was developed by
ECL (GE Healthcare). Gel images were captured by use of a
Image Master III scanner (GE Healthcare), and densitometric
analysis was performed by use of ImageQuant software (GE
Healthcare).
HPLC-MS/MS—Before LC-MS/MS analysis, proteins were
reduced, alkylated, and digested with trypsin according to pre-
viously published methods (20). LC MS/MS analysis was per-
formed by use of a nanoAcquity ultra performance liquid chro-
matography system coupled to quadrupole-time of flight
Premier mass spectrometer (Waters Corp.) at the proteomics
facility of the Institute for Animal Health. Tryptic peptides
were desalted and concentrated on a C18 trap (180 m  20
mm, 5-msymmetry,Waters) for 3min at 10l/minwith 0.1%
(v/v) formic acid and resolved on a 1.7-m BEH 130 C18 col-
umn (100 m 100 mm,Waters). Peptides were eluted at 400
nl/min with a linear gradient of 0–50% (v/v) acetonitrile with
0.1% (v/v) formic acid over 30 min followed by 85% (v/v) aceto-
nitrile with 0.1% (v/v) formic acid for 7 min. Eluted peptides
were analyzed on a quadrupole-time of flight mass spectrome-
ter in data-directed acquisition mode, where a MS survey scan
was used to automatically select multicharged peptides for fur-
ther MS/MS fragmentation. From each survey scan up to three
peptides were selected for fragmentation. MS/MS collision
energy was dependent on precursor ion mass and charge state.
A reference spectrum was collected at every 30 s from the Glu-
fibrinopeptide B (785.8426 m/z), introduced via a reference
sprayer. Two discrete analyses were performed, the second of
which included an exclusion list of all the peptides identified in
the first.
RawMS/MS spectra were processed using ProteinLynx Glo-
bal Server (Waters) and were searched against the IPI murine
protein data base by use of the Mascot search algorithm.
Full processing and search parameters are given in the
supplemental Materials and Methods.
Fibrillization of recPrP—Thismethod follows that previously
published (21). Inclusion bodies were isolated from the appro-
priate bacterial growth as described in the supple-
mental Materials and Methods.RecPrP was purified by metal
ion affinity chromatography, desalted by use of aHiprep desalt-
ing cartridge, and oxidized by the addition of oxidized glutathi-
one overnight. RecPrP was further purified by reverse phase
HPLC, and the protein was lyophilized and stored at 20 °C
until use. Full details of this procedure are given in the
supplemental Materials and Methods.
Recombinantmouse PrPwas fibrillized according to the pro-
tocol published by Breydo et al. (22). Briefly, lyophilized recPrP
was dissolved in 6 M guanidine HCl, pH 6.0, at a concentration
of 3mg/ml. A fibrillization reaction consisting of 2 M guanidine
HCl, 10 mM thiourea, 120 g/ml recPrP, 50 mM MES, pH 6.0,
and 10 M thioflavin T was prepared. 160 l of the reaction
mixture was placed into individual wells of a 96-well plate, and
3 Teflon spheres were added to aid mixing. For inclusion of
LD9-derivedmaterial, proteins from three replicate subcellular
fractionations were pooled and resuspended in 800 l of fibril-
lization buffer. 200 l of each subcellular fraction was added to
a fibrillization reaction, keeping final concentrations of constit-
uents the same. In some reactions 0.1% (w/w) of preformed
recPrP seed was added to the reaction wells. The 96-well plate
was incubated at 37 °C with constant shaking (900 rpm, 1-mm
diameter). The fluorescence from thioflavin T (ThT) was mon-
itored every 5 min by use of a fluorescence plate reader (Fluo-
roskan Ascent, Thermo Scientific) with excitation at 444 nm
and emission at 485 nm.
Background fluorescence was calculated from four replicate
wells containing no recPrP and was subtracted from sample
readings. Sigmoidal curves were fitted to the data where possi-
ble by a least squares approach. Fluorescence, F, at time, t was
calculated from the equation
Ft  A 
B  ct
1  ektm  t
(Eq. 1)
where A is the initial level of ThT fluorescence, B is the peak
level of fluorescence, tm is the mid point of the transition, and k
is the rate of increase of fluorescence. c is an empirical param-
eter describing changes in fluorescence after fibril formation.
The lag time, t1, is calculated as t1 tm 2/k.
RESULTS
LD9 Cell Homogenates Digest recPrP—The identification of
putative co-factors enhancing prion protein misfolding has
been a goal of various studies in recent years. To ensure that
physiological co-factors are identified, we believe that this can
best be achieved through their isolation from defined systems,
such as scrapie-susceptible cell lines, and we chose the LD9
fibroblastic cell line for this purpose because these cells have
been shown to be susceptible to Chandler-derived strains of
scrapie includingME7 and RML (17). LD9 cells were a kind gift
of Charles Weissmann (Scripps, Florida). After homogeniza-
tion of cells, we tested crude homogenates for their ability to
enhance the conversion of recPrP in our cell-free conversion
assay. Briefly, the assay uses a seed of PrPSc, isolated from the
brains of TSE-infected mice, to catalyze the conformational
conversion of recPrP to a PK-resistant isoform. Incorporation
of a 3F4 antibody recognition epitope into the recPrP to create
the construct 3F4-recPrP allows PK-resistant products to be
detected specifically against the background of excess murine
PrPSc by standard Western blotting techniques (23). Initial
CFCA reactions incorporating crude LD9 cell homogenate
yielded an apparent reduction in conversion efficiency relative
to control reactions (data not shown). However, Western blot
signals corresponding to non-PK-treated recPrP also showed
substantial reductions in intensity after CFCA relative to assays
containing no cell homogenate, suggesting LD9 homogenate
either degrades protein or interferes with its detection. Thus,
we tested whether proteases in crude cell homogenates could
degrade the recPrP substrate before its conversion in the
CFCA.We incubated 20ng of3F4-recPrPwith serial dilutions
of LD9 cell homogenate in CFCA buffer without PrPSc and
detected3F4-recPrP byWestern blotting. Fig. 1 shows typical
results of these experiments. At the highest concentration of
cell homogenate tested, no signal corresponding to 3F4-
recPrP can be seen on the Western blot. After dilution of the
homogenate to 1:4000, a signal for 3F4-recPrP was restored,
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but this remains significantly less than that produced by the
control sample. We believe this to be the result of proteases
present in the LD9 cell homogenate, which will presumably
represent a plethora of differentmolecules of different specific-
ities and selectivities. The addition of protease inhibitor cock-
tails to the CFCA is not compatible with subsequent detection
of PK-resistant products by treatment with proteinase K;
hence, we decided to perform subcellular fractionations to
attempt to create fractions that did not have proteases but that
may contain conversion-enhancing cofactors.
LD9 Cells Can Be Fractionated by Use of a Continuous Gra-
dient of OptiPrep—Because putative prion cofactors may be
protein complexes or may require many molecules from a cel-
lular organelle to allow catalysis of misfolding, we focused on a
fractionation regime for LD9 cells that retained organelles as
intact as possible.We homogenized flasks of confluent cells in a
detergent-free, physiological buffer and fractionated by centri-
fugation through a gradient of 10–20% OptiPrep. We carefully
decanted 500-l fractions from the top of the tube to produce
22 discrete subcellular fractions. The molecules contained
within these fractions were precipitated and resuspended in
water, and samples of each fraction were analyzed by SDS-
PAGE and Western blotting using antibodies against specific
markers of the subcellular organelles of interest.
PrP is a plasma membrane protein and, as such, is expressed
in the secretory pathway. Cleavage of N- and C-terminal signal
peptides, disulfide bond formation, and post-translational
modifications take place in the ER/Golgi body complex, and the
mature protein is shuttled to the plasma membrane. PrP is
endocytosed from the cell membrane and routed via endo-
somes for degradation in lysosomes. It has been suggested that
conversion of PrPC to PrPSc takes place on the cell membrane
(24) or during transit on the endocytic pathway (25, 26), and we
chose markers for both plasma membrane (annexin II) and
lysosomes (LAMP-1). We also probed for markers to the ER
(BiP) andGolgi body (23C) because the conformational conver-
sion may conceivably take place in these compartments after
retrograde translocation (27). Finally, overexpression of PrPC
results in its accumulation in mitochondria that leads to neu-
rodegeneration (28). Because this may represent a route of
intracellular trafficking of PrPC that
occurs under native conditions at
undetectable levels but that may be
relevant to disease, we also probed
for mitochondrial-containing sub-
cellular fractions using Bcl-2 as a
marker.
We first demonstrated that each
antibody could be used to detect
subcellular markers by performing
SDS-PAGE separations and West-
ern blotting analyses of crude cell
homogenates (supplemental Fig. 1).
Subsequently, all 22 subcellular
fractionswere analyzed for the pres-
ence of each marker, and typical
Western blots from a subcellular
fractionation of LD9 cells are shown
in Fig. 2. These data indicate that our OptiPrep gradient suc-
cessfully separates the various subcellular organelles. Plasma
membrane is localized in fractions taken from the top of the
gradient, whereas mitochondria are localized toward the bot-
tomof the gradient, as expected based on their knowndensities.
Lysozomes are also located toward the top of the gradient but
extend somewhat lower down the gradient than plasma mem-
brane. The markers for Golgi and endoplasmic reticulum are
spread across more fractions than the other markers probed,
and this is probably the result of partial shearing of these sub-
cellular structures into microsomes during homogenization.
Our intention was not to achieve complete purification of any
subcellular structures by this method, and the 10–20%
OptiPrep gradient provides a useful means of separating LD9
cell homogenates into fractions that are at least enriched for
particular organelles before detailed analysis.
Specific Subcellular Fractions from LD9 Cells Enhance Cell-
free Conversion of PrP—We tested all subcellular fractions from
LD9 cells in our cell-free conversion assay using PrPSc from
ME-7-infected mice as a seed. After each assay we removed a
control sample that was not treated with PK, and the amount of
conversion can be determined by comparing densitometric sig-
nals of bands in PK-treated and untreated samples after West-
ern blotting. For each set of conversion assay reactions, we also
did a negative control reaction (without PrPSc) and a positive
control reaction (with PrPSc but without subcellular fractions).
Representative blots from CFCA experiments incorporating
LD9 fractions are shown in Fig. 3. The protein concentration of
each fraction was unknown, but equal volumes of each fraction
were added to the respective reactions. We found essentially
unaltered conversion efficiencies after the addition of fractions
from the bottom of the OptiPrep gradient (19–22), and frac-
tions from just above this (14–18) appeared to reduce the con-
version efficiency of recPrP slightly. Fractions from in the mid-
dle of the gradient, 7-13, resulted in no conversion of recPrP;
however, there was also little or no detectable recPrP in lanes
that were not treated with PK, suggesting that endogenous LD9
cell proteases were present in these fractions and degraded the
recombinant PrP before conversion could take place. However,
fractions from the top of the OptiPrep gradient showed clear
FIGURE1.LD9homogenatesdigest recombinantPrP.AWesternblot shows the effect of incubationof 20ng
of recPrPwith crude LD9 homogenate at various dilutions. Lanes 7 and 8 contain positive and negative control
samples, respectively. 3F4 antibody was used as the antibody for primary detection.
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signs of increased conversion of recombinant PrP, as deter-
mined by densitometry of Western blot intensities; compare,
for example, lanes 4 and 7 on Fig. 3, panel A. These results
indicate that TSE disease-specific co-factors may be present in
low density subcellular fractions of LD9 cells.
We performed multiple subcellular fractionations of LD9
cells and carried out repeat CFCA reactions supplementedwith
each fraction seededwithME7PrPSc. For fractions 7–13, which
we previously showed resulted in degradation of the recombi-
nant PrP substrate, we first diluted the fraction from the
OptiPrep gradient by 1000-fold, and typical CFCA Western
blots for these experiments are shown in Fig. 4, A and B. These
fractions do not enhance recPrP conversion at 1000-fold dilu-
tion. We chose this dilution because crude homogenates
required dilution of around 1000-fold to prevent excessive deg-
radation of the recPrP substrate during our initial experiments
(see Fig. 1). However, we also investigated the effect of dilution
of fractions 2, 3, and 4 during conversion assays and found that
the enhancing effect was lost after a 200-fold dilution. Thus,
although experiments involving fractions 7–13 represent
extreme dilutions and one would expect the effect of co-factors
to also be diluted, these experiments enable us to say that co-
factors are not likely to be present in fractions 7–13 above the
level that they are present in fractions 1–5.
After densitometric determination of the percentage of
recombinant PrP converted in each reaction and normalization
of data, by setting the amount of converted protein in the pos-
itive control reaction to represent 100% conversion, we aver-
aged the conversion efficiencies, and the results are shown
graphically in Fig. 4C; the error bars represent	 S.D. Although
fractions 7–13 were substantially diluted before the addition in
the CFCA and data from these reactions cannot be compared
directly with those from other fractions, these have been
included on the same graph for illustrative purposes. From
additional subcellular fractionations, we blotted for the five
markers for subcellular organelles in several replicates and
averaged the densitometric intensity of the markers in each
fraction, expressing this as a percentage of the total of each
marker from each fractionation. These data are also displayed
schematically in Fig. 4C. The top-most five fractions from the
OptiPrep subcellular fractionation enhance the conversion effi-
ciency of recombinant PrP seeded withME7 PrPSc; on average,
fraction two approximately doubles the conversion efficiency.
Between fractions 6–15 there appears to be some inhibition of
conversion, perhaps still through partial degradation of the
recombinant PrP substrate. Fractions from the bottom of the
gradient have no significant effect on conversion. By compari-
son with relative quantities of markers for subcellular
FIGURE 2. Representative Western blots are shown for subcellular markers in fractions derived from centrifugation fraction of LD9 homogenates
through an OptiPrep gradient.Western blots are using antibodies specific for BiP (A), 23C (B), annexin II (C), LAMP-2 (D), and Bcl-2 (E).
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organelles, it can be seen that the conversion efficiencies closely
mirror the abundance of annexin II, the plasma membrane
marker. These data suggest that CFCA-enhancing co-factors
may be present in the plasma membrane or other low-density
organelles.
To discount any interfering effects on our CFCA of endoge-
nous PrPC that are present in the LD9 cell lines, we determined
its subcellular location byWestern blotting using 8H4 antibody
(supplemental Fig. 2A). We found that LD9-PrPC was present
in almost all subcellular fractions, a finding that is in agreement
with studies on the cell biology of PrP which indicate that at
different stages of its cell cycle it is present in ER, Golgi, plasma
membrane, and endosomes/lysosomes. By densitometry, we
could show that the levels of LD9-PrPC from each fraction pres-
ent in the CFCA reactions were negligible compared with the
exogenously added recombinant PrP.We conclude that endog-
enous LD9 PrPC is unlikely to contribute either positively or
negatively to conversion of recombinant PrP, although we can-
not rule out that certain forms of PrP at different stages of the
molecule life cyclemay exert more potent stimulatory or inhib-
itory effects on recPrP conversion than others.
Conversion Enhancing Fractions Are Composed of Plasma-
membrane and Cytoplasmic Proteins—To confirm the identi-
ties of proteins present in conversion-enhancing fractions,
we subjected fraction 3 from a subcellular fractionation of
LD9 cells to mass spectrometric analysis. Proteins were
reduced and alkylated with dithiothreitol and iodoacet-
amide, respectively, and were digested by the addition of
trypsin. The tryptic peptides were analyzed by online capil-
lary HPLC-MS/MS, and MS/MS spectra were searched
against a non-redundant data base using the Mascot search
algorithm. Proteins identified above the significance thresh-
old and for which at least two peptides were identified and
withMascot scores of
200 are listed in Table 1. TheMascot
FIGURE 3. Shown are representative Western blots of the effect of LD9 subcellular fractions on the conversion of 3F4-recPrP seeded with PrPSc
derived fromME7-infectedmouse brains. Panels A–E show the addition of sequential subcellular fractions from OptiPrep gradients to the cell free conver-
sion assay along with negative controls (lanes 1 and 2) and positive controls (lanes 3 and 4). For the CFCA reaction, samples without and with proteinase K
treatment are included on the Western blot. The densitometric intensity of the PK lane (19/20th of the sample) is compared with the intensity of the
respectivePK lane (1/20th of the sample) to yield % conversion.
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output can be accessed in the supplemental Materials and
Methods. From the Uniprot and Ingenuity knowledge bases,
we extracted known and predicted subcellular localization
information. The majority of proteins identified were cyto-
plasmic, and this is in agreement with the presence of pro-
teins that are not contained within discrete organelles in the
upper fractions of the gradient. However, we also detected a
number of plasma membrane-specific proteins in this frac-
tion. The low efficiency of detection of plasma-membrane
proteins by MS approaches is well known, and the over-
whelming bias of cytoplasmic proteins detected in fraction 3
over membrane proteins may reflect the poor detection of
such proteins by MS. Nevertheless, fractions from the upper
portion of the OptiPrep gradient clearly contain both cyto-
plasmic and plasma membrane proteins.
Buoyant Fractions fromAnother Scrapie-susceptibleCell Line
also Enhance PrP Conversion—We wanted to investigate
whether the enhancement of conversion by buoyant LD9 sub-
cellular fractions was a property only of this cell line or whether
similar fractions from other TSE-susceptible cell lines would
also enhance conversion. For this purpose we cultured scrapie
mouse brain (SMB-PS) cells obtained from the TSE Resource
Centre. This cell line was originally grown ex vivo from the
brain of a mouse infected with scrapie and was subsequently
FIGURE 4.A, and B, shown are representativeWestern blots of the effect of LD9 subcellular fractions 7–13 at a 1:1000 dilution on the conversion of3F4-recPrP
seededwith PrPSc derived fromME7-infectedmousebrains. Thedensitometric intensity of thePK lane (19/20th of the sample) is comparedwith the intensity
of the respectivePK lane (1/20thof the sample) to yield%conversion.C,bar chartandcolorheatmapshowingaveragedconversionefficiency in thepresence
of subcellular fractions (n4, error barsare	S.D.; * indicates results that are statistically significantlydifferent fromcontrolsbyStudent’s t test (p0.05)) along
with the averaged abundance of subcellular markers in each fraction (n
 3).
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cured of TSE infection by treatment with pentosan polysulfate
(29). The cured cell line has been shown to be susceptible to
multiple mouse-passaged scrapie strains, although not all
strains lead to a stable infection.
Using an identical OptiPrep gradient to that used previously,
we fractionated homogenates of SMB-PS cells and blotted for
the five markers for ER, Golgi body, plasma membrane, lyso-
somes, and mitochondria. We found tighter distributions of
both ER and Golgi markers in SMB cell gradient fractions com-
pared with LD9 cells, and markers for mitochondria and lyso-
somes showed a similar distribution to those found for LD9 frac-
tionations (supplemental Fig. 3). In addition, annexin II, the
plasmamembranemarker, was found in the top-most fractions of
SMB cell gradients. We also found that SMB-PS cells contained
negligible levels of endogenous PrPC compared with the amount
of recPrP added to the CFCA reactions (supplemental Fig. 2B).
We incubated SMB-PS subcellular fractions in CFCA reac-
tions seeded with ME7. To reduce the significant amount of
PrPSc used in such experiments, we focused only on the top five
fractions from the gradient, the equivalent to those LD9 frac-
tions that enhanced conversion. Fig. 5A shows a typical West-
ern blot from these experiments. We repeated the subcellular
fractionation and the CFCA several times, and the average
effect on conversion of recombinant PrP of each fraction was
calculated. Normalized conversion efficiencies relative to
CFCA reactions in which no subcellular fractions were added
for the five upper fractions of the gradient are shown graphi-
cally in Fig. 5B and are 	S.D. We found that the top-most
fractions of SMB-PS cell gradient fractionations also signifi-
cantly enhanced conversion of recombinant PrP using ME7
PrPSc as seed.Thesedata indicate that thisphenomenon isnotcell
line-specific, thereby suggesting that conversion-enhancing
co-factors are present in various cell lines. Whether cell lines that
are incapableof sustainingTSE infectionsalsopossess conversion-
enhancing co-factors remains to be determined.
LD9 Fractions Enhance Conversion of PrP Seeded with a Dif-
ferent TSE Strain—We also asked whether any co-factors pres-
ent in LD9 cells were TSE strain-specific. We performed addi-
tional fractionations of LD9 cells and incubated them in CFCA
reactions seeded with PrPSc purified from the brains of mice
infected with the 79A strain of mouse-passaged scrapie. Con-
version using 79A as a seed is inefficient, and average percent-
age conversion of positive controls were an order of magnitude
less than for ME7-seeded conversion assays. As a result, varia-
tions in conversion efficiency caused by experimental differ-
ences were correspondingly larger, making it difficult to inter-
pret the effect of addition of LD9 subcellular fractions.
Nevertheless, we carried out two repeats of CFCA reactions
including only fractions 2–4 from LD9 subcellular gradients as
sources of co-factors, and we averaged the conversion efficien-
cies. A typicalWestern blot from these experiments is shown in
Fig. 6A, and averaged conversion efficiencies are plotted graph-
TABLE 1
List of proteins identified as present in fraction 3 from subcellular fractionation of LD9 cells
Proteins were reduced, alkylated, and digested with trypsin, and the resulting peptides were analyzed by online HPLC-MS/MS. Peptide MS/MS data was searched against
the ISI Mouse database using the Mascot search algorithm. Proteins with greater than two peptide hits and Mascot Mowse scores greater than 200 are reported here. Full
results are given in the supplemental “Materials and Methods.” PM, plasma membrane.
Gene name Protein name Peptide hits Mascot protein score Primary cellularlocation
Actb Actin, various forms 3–26 179–3121 Cytoplasm
Tubb5 Tubulin, various forms 5–18 112–1493 Cytoplasm
Hspa8 Heat shock cognate 71-kDa protein 19 1172 Cytoplasm
Eno1 -Enolase 13 845 Cytoplasm/PM
Hsp90ab1 Heat shock protein 90-kDa  (cytosolic) 20 838 Cytoplasm
Tpi1 Triosephosphate isomerase 1 8 596 Cytoplasm
Ppia Peptidyl-prolyl cis-trans isomerase 7 555 Cytoplasm
Prdx6 Peroxiredoxin-6 4 549 Cytoplasm/lysosome
Got1 Aspartate aminotransferase, cytoplasmic 5 537 Cytoplasm
Anxa5 Annexin A5 5 511 PM
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 5 474 Cytoplasm/PM
Pgam1 Phosphoglycerate mutase 1 5 461 Cytoplasm
Ywhaz 14-3-3 protein / 7 444 Cytoplasm
Arhgdia Rho GDP-dissociation inhibitor 1 6 403 Cytoplasm
Pgk1 Phosphoglycerate kinase 1 6 390 Cytoplasm
Gdi2 Isoform 1 of Rab GDP dissociation inhibitor  4 365 Cytoplasm/PM
Hsp90aa1 Heat shock protein HSP 90 12 356 Cytoplasm
Ywhab Isoform Long of 14-3-3 protein / 4 352 Cytoplasm
Ywhaq Isoform 1 of 14-3-3 protein 	 3 337 Cytoplasm
Gsn Isoform 1 of Gelsolin 5 307 Extracellular space
Eif4b Eukaryotic translation initiation factor 4B 2 303 Cytoplasm
Lgals1 Galectin-1 6 273 Extracellular space
Cfl1 Cofilin 1 3 264 Cytoplasm/nucleus
Phgdh D-3-Phosphoglycerate dehydrogenase 6 255 Cytoplasm
Akr1b3 Aldose reductase 4 248 Cytoplasm
Nme2 Nucleoside diphosphate kinase B 4 246 Nucleus
Fdps Farnesyl pyrophosphate synthetase 4 233 Cytoplasm
Anxa1 Annexin A1 3 231 PM
Ywhag 14-3-3 Protein 
 2 221 Cytoplasm
Eif4a1 Eukaryotic initiation factor 4A-I 4 221 Cytoplasm
Gstm1 Glutathione S-transferase 1 4 218 Cytoplasm
Uap1l1 Isoform 1 of UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 3 212 Unknown
Gsto1 Glutathione S-transferase 1 3 209 Cytoplasm
Eno3 -Enolase 3 202 Cytoplasm
Pebp1 Phosphatidylethanolamine-binding protein 1 2 202 Cytoplasm
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ically in Fig. 6B. Although differences in relative conversion
efficiency are not statistically significant, the data appear to
show that low density LD9 cell fractions also enhance conver-
sion of recombinant PrP seeded with 79A. These results indi-
cate either that co-factors contained in LD9 cells are not TSE
strain-specific or that LD9 cells possess different sets of co-
factors capable of enhancing conversion by different strains of
TSE disease.
LD9 Subcellular Fractions That Enhance Cell-free Conver-
sion Inhibit in Vitro Fibrillization of PrP from Two Different
Species—Finally, we hypothesized that cofactors that enhance
PrP conversion seeded with exogenous PrPSc may also catalyze
the general misfolding of PrP in
alternate in vitro reactions. We
fibrillized murine PrP by continu-
ous shaking (22) in the presence or
absence of the 22 LD9 subcellular
fractions, monitoring fibril forma-
tion by the increase in ThT fluores-
cence. In the first experiment we
performed four repeat fibrillizations
of each sample and fitted sigmoidal
curves to the data by least squares
approaches to allow measures of
fibrillization lag times to be derived.
Fig. 7, panels A–D, show repeat
fibrillizations from samples con-
taining fractions 1, 2, 3, or 8. Fibril-
lization of murine PrP in the pres-
ence of fraction 1 is not significantly
different from control fibrillizations
(shown in supplemental Fig. 4).
However, in the presence of fraction
2, the lag time for fibrillization is
extended to the point where fibrilli-
zation is only just beginning to
occur at the end of the assay period
(24 h). No fibrillization is evident in
samples containing LD9 fractions 3
or 4, whereas samples containing
fraction 5 just begin to fibrillize
within the assay time frame again.
The addition of fractions 6 and 7
produce fibrillization profiles that
are essentially complete within the
time scale of the experiment but
have significantly longer lag times
than control fibrillizations, whereas
the addition of fraction 8 yields
fibrillization curves that are not sig-
nificantly different from controls.
We confirmed that the rise in ThT
fluorescence does indeed correlate
to the formation of fibrils by con-
firming the presence of a PK-resist-
ant product after maturation of
fibrils, according to the protocol
by Breydo et al. (22) (supple-
mental Fig. 5). Thus, low density fractions that enhance PrPSc-
seeded conversion of recPrP also inhibit in vitro fibrillization of
the same protein.
Fibrillization is believed to occur exponentially after creation
of an initial nucleation complex. To determine whether low
density LD9 fractions slowed nucleation of a seed or whether
elongation of fibrils after nucleation was slowed, we performed
a second set of fibrillization experiments where we added pre-
formed fibrils to half of the samples before fibrillization. In con-
trol fibrillization assays without added LD9 fractions, the pres-
ence of preformed fibrils shortened lag times dramatically. In
the presence of LD9 fractions, lag times to fibrillization of
FIGURE 5. A, shown are Western blots of the effect of SMB-PS subcellular fractions 1–5 on the conversion of
3F4-recPrP seeded with PrPSc derived from ME7-infected mouse brains. B, shown is a bar chart of average
conversion efficiency of3F4-recPrP seededwithME7 in the presence of SMB-PS subcellular fractions 1–5. n
3. Error bars are	 S.D.; * indicates results that are statistically significantly different from controls by Student’s
t test (p 0.05).
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seeded assays were always shorter than unseeded assays. How-
ever, for fractions that completely abrogated fibrillization of
unseeded assays, the addition of preformed seed caused fibril-
lization to proceed but at a substantially reduced rate of fibril-
lization. Therefore, we conclude that low density LD9 fractions
negatively affect both the nucleation and elongation steps of
fibrillization.
The full results from all fibrillization experiments using
murine PrP are given in supplemental Fig. 4, from which aver-
age lag times of both seeded and unseeded reactions were cal-
culated. For fractions 2, 3, and 4, lag times could not be calcu-
lated because sigmoidal curves could not be fit to partial
fibrillization data with accuracy. The lag times are presented
graphically in Fig. 7E, and it can clearly be seen that fractions
which enhanceCFCA-specific conversion of recPrP also inhibit
both seeded and unseeded fibrillization ofmurine PrP. For frac-
tions 5, 6, and 7, the lag time differences relative to control
samples are statistically significant, as determined by Student’s
t test. Interestingly, unseeded reactions incorporating fractions
10 and 11 are also significantly different from controls (p 
0.05), but the corresponding seeded reactions are not signifi-
cantly different. We are currently unsure of the cause of this
difference but are undertaking experiments to confirm these
results.
DISCUSSION
Various in vitro assays have been developed to allow the
study of prion protein conformational change, and some assays
replicate aspects of TSE disease. The original cell free conver-
sion assaywas pioneered by the group ofCaughey and co-work-
ers (16) in the 1990s. The assay included radiolabeled recPrP
derived from tissue culture as a substrate, and we subsequently
modified this assay to use radiolabeled PrP derived from
recombinant bacteria (15). Our CFCA has been shown to rep-
licate many aspects of TSE disease, including reduced conver-
sion across species barriers, the effect of amino acid changes in
the PrP protein on conversion, and inhibition of conversion by
known anti-TSE drugs (30). Conversion efficiencies in this
assay are low, however, and there is a need to include an excess
of seed over substrate to drive conversion. The low conversion
efficiency is in line with the exceptionally long incubation times
associated with TSE disease. Of crucial importance is that the
output from the CFCA is a measure of the efficiency of the
conversion of the substrate; thus, changes in conversion effi-
ciency that result from alterations to assay conditions can be
quantified.6
More recently, two additional assays have been developed
that use the same basic principle as the CFCA but include addi-
tional factors resulting in dramatically increased levels of con-
version. The PMCAassay uses brain homogenate from scrapie-
infected animals to seed conversion of native PrPC contained in
brain homogenate from uninfected animals (5). The assay also
incorporates sequential rounds of sonication, incubation, and
dilution of the assay constituents into uninfected brain homo-
genate to dilute out the starting seed and to replenish the sub-
strate. A similar assay, termed quaking induced conversion,
uses PrP from recombinant bacteria as a substrate and inter-
mittent shaking to drive conversion (12). Like the PMCA assay,
sequential rounds of dilution into fresh substrate can dilute out
the starting PrPSc, but the protease-resistant recombinant pro-
tein produced has not been shown to be infectious. Thus,
although the quaking-induced conversion assay appears to pro-
duce PK-resistant recombinant protein when it is seeded with
PrPSc, this may not represent a disease-specific misfolding of
recombinant PrP but, rather, a fibrillization catalyzed by the
presence of pre-aggregated protein. Crucially, it has also been
shown that continual shaking of recombinant PrP alone even-
tually produces amyloid fibrils that resemble PrPSc (32), which
caused disease in transgenic mice overexpressing PrP (13).
6 Kirby, L., Agarwal, S., Graham, J., Goldmann, W., and Gill, A. C. (2010) Bio-
chemistry 49, 1448–1459.
FIGURE 6.A, shown areWestern blots of the effect of LD9 subcellular fractions
2–4 on the conversion of 3F4-recPrP seeded with PrPSc derived from 79A-
infectedmousebrains.B, shown is abar chartof averageconversionefficiency
of 3F4-recPrP seeded with 79A in the presence of LD9 subcellular fractions
2–4. Error bars are	 S.D.; n 2.
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Both CFCA and quaking-induced conversion assays use
recombinant protein as a substrate and differ from the PMCA
assay in that normal brain homogenate is added to this assay as
the source of PrPC substrate. The addition of brain homogenate
presumably allows the generation not only of PK-resistant pro-
tein but also of TSE infectivity, a disease-specific process. These
observations strongly suggest the presence of co-factors pres-
ent in brain that promote disease-specific folding of PrP, which
FIGURE 7. Panels A–D show graphs of ThT fluorescence as a function of time during fibrillization of recPrP in the presence of LD9 fraction 1 (A), LD9 fraction 2
(B), LD9 fraction 3 (C), and LD9 fraction 8 (D). E, shown is a bar chart showing average lag times to fibrillization of recPrP in the presence of LD9 fractions.Dotted
bars represent lag times of reactions that were not seeded with preformed fibrils, and striped bars represent reactions that were seeded with 0.1% (w/w)
preformed fibrils. Error bars are	 S.D.; n 6 for unseeded and 2 for seeded reactions. An asterisk indicates lag times that are significantly different relative to
control reactionswithnoLD9 fraction added. Lag times for reactions involving fractions 2–4 couldnotbe calculatedbecauseno fibrillizationwas evident in the
time scale of the experiment.
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results in the generation of de novo infectivity. Identification of
these factors would increase our understanding of TSE diseases
immeasurably, and in our current experiments we have isolated
specific low density, subcellular fractions that cause an increase
in conversion efficiency of recPrP in our CFCA. Our CFCA
does not use shaking, sonication, or other exogenous sources of
energy; thus, we suggest that the observed increase in conver-
sion efficiency may be a physiological process. Those fractions
that stimulated disease-specific conversion of recPrP came
from the upper (lowdensity) regions of the centrifugal gradient;
Western blotting for subcellular markers showed this region to
contain the plasmamembranemarker annexin II, and therewas
partial overlap with the lysosomal marker, LAMP2. The con-
version-enhancing fractions were distinct from those contain-
ing markers for Golgi body, ER, or mitochondria, implying that
these organelles do not contain prion co-factors.
To confirm that conversion-enhancing fractions contained
plasma membrane proteins, we analyzed one such fraction by
proteomic techniques and identified 42 different proteins that
are contained within this fraction. The majority of these pro-
teins are localized predominately in the cytoplasm, but a hand-
ful of plasma membrane-specific proteins were also identified.
Mass spectrometric techniques for protein identification are
known to under-represent membrane proteins because their
hydrophobic nature makes analysis problematic, and it is not
clear whether the relative numbers of cytoplasmic versus
plasmamembrane proteins identified are a true representation
of the contents of this fraction. From our list of proteins it is
tempting to speculate on the involvement of particular proteins
in conversion. Certainly, various heat shock proteinswere iden-
tified in LD9 fraction 3, and the enhancement of conversion of
recPrP by molecular chaperones has previously been docu-
mented (33). In yeast, heat shock proteins are of crucial impor-
tance in mediating the prion phenotypes (34–36) and may also
mediate aggregation of various mammalian proteins (37).
Additionally, cytoskeletal proteins present in LD9 fraction 3
may create a scaffold that helps catalyze the conformational
change of PrP leading to aggresome formation. This mecha-
nism of prion formation has also been suggested in yeast (38),
and there is some evidence for aggresome formation in mam-
malian TSEs (39). However, presently we do not knowwhich, if
any, of the identified proteins is the active component, and
future work will involve subfractionation of active fractions.
We also note that plasma membrane proteins are likely to be
isolated from OptiPrep gradients in the presence of small sec-
tions of themembrane, thereby co-purifying with various lipids
and potentially glycosaminoglycans. We have not tested our
active fractions for either class ofmolecule, but if present, either
may have effects on conversion. Both glycosaminoglycans (40–
42) and lipids (43–45) have previously been suggested as poten-
tial prion cofactors. In addition, Deleault’s minimal constitu-
ents for prion replication by PMCA (14) includes lipids that
co-purify with the PrPC substrate and poly(A)RNA, which is a
polyanionic compound andwhichmay take the place of glycos-
aminoglycans in vitro. Heparin sulfate as well as other polyan-
ionic compounds has also been shown to be an effective catalyst
for prion misfolding in the PMCA assay (31). It is possible that
our low density fractions contain similar constituents to those
suggested by Deleault, but at this stage a thorough analysis of
the chemical composition of these fractions is not useful as a
wide variety of differentmoleculesmay be present within active
fractions; further fractionation will allow us to segregate those
molecules that participate in conversion from those that hap-
pen to co-isolate with them.
To test the specificity of our findings, we performed experi-
ments with PrPSc from another source of mouse scrapie as seed
and also used an additional scrapie-susceptible cell line to pro-
vide the source of subcellular fractions. In both cases we found
that low density fractions enhanced conversion. At face value,
this result implies a certain lack of specificity of the putative
cofactors contained in our low density fractions. SMB-PS cells
are not susceptible to stable infection with ME7 scrapie, but
transient infection can occur,7 and LD9 cells have not been
reported to be infected by 79A scrapie (17). Thus, onemight not
expect SMB-PS cells to possess co-factors that can cause con-
version of recPrP seeded by ME7, and LD9 cell co-factors may
not catalyze misfolding seeded with 79A. However, we still
know little about why particular cell lines are susceptible to
scrapie infection, whereas others are not (8). It is possible that
all cells, regardless of origin, are capable of converting PrPC to a
variety of different isoforms but that certain cell lines clear par-
ticular isoforms of PrPSc more readily than others, preventing
stable infection with specific TSE strains. Our results suggest
that a variety of different cell lines would also be able to supply
lowdensity fractions that enhance conversion; in effect, wemay
be creating a cell-free environment highly amenable to prion
misfolding but which contains the necessary molecules for effi-
cient conversion of recPrP in the absence of molecules for effi-
cient removal of PrPSc.
To test the possibility that conversion-enhancing fractions
created optimal conditions for prion misfolding, we used a
fibrillization assay to monitor the effect of subcellular fractions
on PrP folding in the absence of a PrPSc seed (22). Our findings
are unexpected and indicate that the same fractions that
enhance disease-specific misfolding of recPrP also inhibit in
vitro fibrillization.When the fibrillization was seeded with pre-
formed fibrils of recombinant PrP, produced previously by
shaking-induced fibrillization, the lag times of fibrillization in
the presence of low density LD9 fibrils were shortened, but
fibrillization did not go to completion in the time scale of the
assay. Thus, low density LD9 fractions inhibit both initial seed
formation and fibril elongation. It is difficult to interpret these
results mechanistically, as detailed molecular mechanisms of
seeded CFCA and unseeded fibrillization reactions are not
known. However, we have recently analyzed the effects of prion
protein polymorphisms on both assays and found several poly-
morphisms that inhibited recPrP conversion in the CFCA yet
enhanced oligomerization of the same protein.6 We found sig-
nificant differences between stability of the recPrP variants
used in these experiments, which correlated with the effects on
disease-specific and non-disease specific misfolding. Because
our previous data are essentially the reverse of those outlined
herein, we believe that the effect of low density LD9 fractions
7 R. Hennion, IAH Compton, personal communication.
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may be to stabilize the structure of recPrP. It is known that the
CFCA requires a well folded substrate for conversion to pro-
ceed effectively. In vitro fibrillization, on the other hand, pro-
ceeds by denaturation of the recPrP by inclusion of chaotropes
in the assay buffer.
In summary, we present data demonstrating the production
of low density, subcellular fractions from two different scrapie-
susceptible cell lines that enhance disease-specific misfolding
of recombinant prion protein. The active fractions from one
cell line is effective in enhancing conversion when the reaction
is seeded with PrPSc from two different strains of scrapie, and
taken together, these data suggest that the ability of TSE strains
to infect cellsmay be governed by differential clearance of prion
aggregates rather than a lack of ability of cells to convert endog-
enous PrPC to particular abnormal isoforms. Furthermore, we
find that the low density fractions of LD9 cells that enhance
disease-specific conversion inhibit in vitro fibrillization of
recPrP, suggesting that different mechanisms are involved in
eachmisfolding reaction. The active fractions are composed of,
at minimum, plasma membrane and cytoplasmic proteins, and
experiments to define further their critical components are
ongoing.
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